This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bang, P. Articles by Fielder, P. J. Search for Related Content PubMed PubMed Citation Articles by Bang, P. Articles by Fielder, P. J.

Human Pregnancy Serum Contains at Least Two Distinct Proteolytic Activities with the Ability To Degrade Insulin-Like Growth Factor Binding Protein-3¹

Pediatric Endocrinology Unit, Department of Women and Child Health, Karolinska Hospital and Institute (P.B.), Stockholm Sweden; and Department of Pharmacokinetics and Metabolism, Genentech Incorporated (P.J.F.), South San Francisco, California 94080

The presence of a proteolytic activity in sera from pregnant humans and rodents capable of degrading insulin-like growth factor binding protein-3 (IGFBP-3) has been known for some time. However, the identity of this activity has remained elusive. We have attempted to purify the IGFBP-3 protease activity from pregnant human serum (PHS) using the degradation of ¹²⁵I-IGFBP-3 as a marker. Following ammonium sulfate precipitation of PHS and further enrichment of active fractions by ion-exchange, protein-A Sepharose, and size-exclusion chromatography, a protease of approximately 70–90 kDa was isolated and subjected to N-terminal analysis. The N-terminal sequence was consistent with plasminogen, a known fibrinolytic enzyme. To further characterize the IGFBP-3 protease activities in both PHS and nonpregnant human serum (NHS), aliquots of serum were first enriched by polyethylene glycol-precipitation and subjected to size-exclusion chromatography. The size-separated fractions were then incubated with ¹²⁵I-IGFBP-3, and proteolytic activity was measured. PHS contained two separate proteases (>150 kDa and 70–90 kDa), whereas NHS contained only one (70–90 kDa) that had a inhibitor profile similar to plasmin. However, inhibitors of plasmin had no effect on the activity of the >150-kDa protease. Plasminogen activators (PAs) greatly increased the activity of the 70- to 90-kDa protease, but had little effect on the >150-kDa protease activity. Addition of PAs greatly increased the ability of NHS to proteolyze IGFBP-3. In contrast, the ability of plasminogen-depleted plasma to degrade ¹²⁵I-IGFBP-3 was not affected by the addition of PAs. Both urokinase and tissue-type PA had the ability to proteolyze IGFBP-3 and were, in contrast to the >150-kDa protease activity, inhibited by the specific PA inhibitor D-PHE-PRO-ARG chloromethyl ketone. The present data suggest that sera has the ability to proteolyze IGFBP-3, and that this ability, as demonstrated by NHS, can be regulated by protease inhibitors and PAs. In addition, PHS does indeed contain an unique IGFBP-3 protease activity that is not present in NHS, and its identity is unknown at this time.

This article has been cited by other articles:

				N. Wilczak, J. W. Elting, D. Chesik, I. P. Kema, and J. De Keyser Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like Growth Factor-1 Stroke, September 1, 2006; 37(9): 2368 - 2371. [Abstract] [Full Text] [PDF]

				H. G. Skinner, D. S. Michaud, G. A. Colditz, E. L. Giovannucci, M. J. Stampfer, W. C. Willett, and C. S. Fuchs Parity, Reproductive Factors, and the Risk of Pancreatic Cancer in Women Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 433 - 438. [Abstract] [Full Text] [PDF]

				D. Byun, S. Mohan, M. Yoo, C. Sexton, D. J. Baylink, and X. Qin Pregnancy-Associated Plasma Protein-A Accounts for the Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Proteolytic Activity in Human Pregnancy Serum and Enhances the Mitogenic Activity of IGF by Degrading IGFBP-4 in Vitro J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 847 - 854. [Abstract] [Full Text]

				C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314. [Abstract] [Full Text] [PDF]

				G. R. Devi, D.-H. Yang, R. G. Rosenfeld, and Y. Oh Differential Effects of Insulin-Like Growth Factor (IGF)-Binding Protein-3 and Its Proteolytic Fragments on Ligand Binding, Cell Surface Association, and IGF-I Receptor Signaling Endocrinology, November 1, 2000; 141(11): 4171 - 4179. [Abstract] [Full Text] [PDF]

				H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF]

				J. C. Irwin, L.-F. Suen, B.-H. Cheng, R. Martin, P. Cannon, C. L. Deal, and L. C. Giudice Human Placental Trophoblasts Secrete a Disintegrin Metalloproteinase Very Similar to the Insulin-Like Growth Factor Binding Protein-3 Protease in Human Pregnancy Serum Endocrinology, February 1, 2000; 141(2): 666 - 674. [Abstract] [Full Text] [PDF]

				B. A. Booth, M. Boes, B. L. Dake, and R. S. Bar Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3 Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E450 - E454. [Abstract] [Full Text] [PDF]

				L. A. Maile, S. Xu, S. C. Cwyfan-Hughes, J. K. Fernihough, J. M. Pell, and J. M. P. Holly Active and Inhibitory Components of the Insulin-Like Growth Factor Binding Protein-3 Protease System in Adult Serum, Interstitial, and Synovial Fluid Endocrinology, December 1, 1998; 139(12): 4772 - 4781. [Abstract] [Full Text] [PDF]

				B. Kubler, S. Cowell, J. Zapf, and T. Braulke Proteolysis of Insulin-Like Growth Factor Binding Proteins by a Novel 50-Kilodalton Metalloproteinase in Human Pregnancy Serum Endocrinology, April 1, 1998; 139(4): 1556 - 1563. [Abstract] [Full Text] [PDF]